ck1δ

D4476 (Casein Kinase I Inhibitor) is an effective, selective, and cell-permeant CK1 (casein kinase 1) inhibitor( IC50=300 nM in a cell-free assay).

Casein kinase 1δ-IN-1 (WAY-643895) is an inhibitor of casein kinase 1δ (CK1δ) and can be utilized in the study of neurodegenerative diseases, such as Alzheimer's disease.

PF-5006739 is an effective and selective inhibitor of CK1δ/ε (IC50s: 3.9 nM and 17.0 nM, respectively). PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selecti

CK1δ-IN-3 (compound 376) is a CK1δ (casein kinase 1δ) inhibitor that can be used to study neurodegenerative diseases such as Alzheimer's disease.

LY-364947 (HTS466284) is a potent ATP-competitive inhibitor of TGFβR-I.

CK1δ-IN-6 (Compound 303) is an inhibitor of Casein kinase 1δ, with potential applications in Alzheimer's disease research.

CK1δ/CK1ε ligand-1 is a ligand of CK1δ/CK1ε and can serve as a target protein ligand for the synthesis of the CK1 PROTAC degrader AH078.

CK1δ-IN-7 (Compound 488) is an inhibitor of casein kinase 1δ (CK1δ).

CK1δ-IN-10 (Compound 85) is an inhibitor of casein kinase 1 (CK1), specifically targeting CK1δ (CSNKID), with an IC50 value of 0.255 μM.

CK1δ-IN-5 (Compound 24) is an inhibitor of casein kinase 1δ (CK1δ) and can be used in the study of neurodegenerative diseases.

CK1δ-IN-9 (Compound 8) is an inhibitor of casein kinase 1 (CK1), specifically targeting CK1δ with an IC50 of 1.4 nM. The compound also inhibits p38α and p38β with IC50 values of 0.25 μM and 0.78 μM, respectively. CK1δ-IN-9 exhibits favorable pharmacokinetic properties, including high oral bioavailability (70%) and moderate clearance.

CK1δ-IN-8 (Compound 429) is a CK1δ inhibitor suitable for Alzheimer's disease research.

p38αMAPK/CK1δ inhibitor-1 (Compound 3) exhibits inhibitory activity against p38αMAPK and CK1δ, with IC50 values of 0.185 µM and 0.089 µM, respectively.

SR-3029 is a highly potent and specific inhibitor of CK1δ/CK1ε.

TA-01 is a potent inhibitor of CK1 and p38 MAPK, with IC50 values of 6.4 nM for CK1ε, 6.8 nM for CK1δ, and 6.7 nM for p38 MAPK.

Casein kinase 1δ-IN-3 (Compound 23a) is an inhibitor of casein kinase 1 delta (CK1δ) with a pIC50 of 6.5376 M.

Casein kinase 1δ-IN-6 is a potent and selective inhibitor of the protein kinase CK-1δ with an IC50 of 23 nM, demonstrating neuroprotective and anti-inflammatory activity in both in vitro and in vivo assays. Casein kinase 1δ-IN-6 can be used to study neurodegenerative diseases.

CK1-IN-3 is casein kinase 1 (CK1) inhibitor and can be used for research on the treatment or prevention of diseases associated with circadiantiazol rhythm, inflammation diseases.

Epiblastin A is an inhibitor of Casein Kinase 1 (CK1). Epiblastin A engages CK1 isoenzymes in cell lysate and induces efficient conversion of epiblast stem cells (EpiSCs) into embryonic stem cells (cESCs).

CKI-7 is a potent, ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor. It also inhibits SGK, ribosomal S6 kinase-1 (S6K1), and MSK1.

AMG-548 is a selective and orally active p38α MAPK inhibitor (Ki = 0.5 nM), with higher selectivity than p38β, p38γ, and p38δ, and can also inhibit the TNFα, CK1δ/ε, and Wnt signalling pathways.

LH846 is a selective inhibitor of CK1δ with IC50 values of 290 nM for CK1δ, 1.3 μM for CK1ε, and 2.5 μM for CK1α, and exhibits no inhibitory activity at CK2.

CK1-IN-1 (PUN51207) is a casein kinase 1 (CK1) inhibitor. CK1-IN-1 has IC50s of 15 nM, 16 nM, 73 nM for CK1δ, and CK1ε, p38σ MAPK, respectively.

CKI-7 free base is a potent, ATP-competitive inhibitor of casein kinase 1 (CK1; IC50: 6 μM; Ki: 8.5 μM) and a selective Cdc7 kinase inhibitor, also inhibiting SGK, ribosomal S6 kinase-1 (S6K1), and MSK1.